A compound of Formula: and/or a pharmaceutically acceptable salt thereof, wherein: W is -O-P-Q-C(R 8a)=C(R 8b)(R 8c); P is -alkyl-N -, -alkyl-(C 3 -C 6)cycloalkyl-N -, -alkyl-O-alkyl-N -, Z and Z 1 are independently a covalent bond, -alkyl-, -alkyl-O-, -alkyl-N -, or -alkyl-O-alkyl-, with the proviso that Z is connected to ring A at a carbon atom adjacent to the ring nitrogen atom; ring A with the ring nitrogen atom shown is an optionally substituted saturated mono- or multicyclic 4 to 10 membered heterocyclyl; ring J with the ring nitrogen atom and ring Y 1 atom shown is a saturated 4 to 10 membered heterocyclyl; Y 1 is C or N; Z 2 is a covalent bond or N, with the proviso that when Y 1 in ring J is nitrogen, then Z 2 is a covalent bond; each R is independently hydrogen, or alkyl; Q is -C(=O)- or -S(=O) 2 -; R 8a is hydrogen, halogen, or cyano; R 8b is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocyclyl; or R 8a and R 8b are taken together to form a bond; and R 8c is hydrogen or optionally substituted alkyl; R b1 is optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocyclyl; and R b2 and R b3 are independently hydrogen or optionally substituted alkyl; or R b2 and R b3 together with the boron atom to which they are shown attached form a cyclic boronic ester; or a compound selected from the group consisting of: ( -1-(3-(( -1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methoxy)propanamido)-2-phenylethyl)boronic acid; ( -1-(3-(1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)propanamido)-2-phenylethyl)boronic acid; and ( -1-(3-(1-(2-cyano-4-methylpent-2-enoyl)piperidin-2-yl)propanamido)-2-phenylethyl)boronic acid; an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds. W is -O-P-Q-C(R 8a)=C(R 8b)(R 8c); P is -alkyl-N -, -alkyl-(C 3 -C 6)cycloalkyl-N -, -alkyl-O-alkyl-N -, Z and Z 1 are independently a covalent bond, -alkyl-, -alkyl-O-, -alkyl-N -, or -alkyl-O-alkyl-, with the proviso that Z is connected to ring A at a carbon atom adjacent to the ring nitrogen atom; ring A with the ring nitrogen atom shown is an optionally substituted saturated mono- or multicyclic 4 to 10 membered heterocyclyl; ring J with the ring nitrogen atom and ring Y 1 atom shown is a saturated 4 to 10 membered heterocyclyl; Y 1 is C or N; Z 2 is a covalent bond or N, with the proviso that when Y 1 in ring J is nitrogen, then Z 2 is a covalent bond; each R is independently hydrogen, or alkyl; Q is -C(=O)- or -S(=O) 2 -; R 8a is hydrogen, halogen, or cyano; R 8b is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocyclyl; or R 8a and R 8b are taken together to form a bond; and R 8c is hydrogen or optionally substituted alkyl; R b1 is optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocyclyl; and R b2 and R b3 are independently hydrogen or optionally substituted alkyl; or R b2 and R b3 together with the boron atom to which they are shown attached form a cyclic boronic ester; or a compound selected from the group consisting of: ( -1-(3-(( -1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methoxy)propanamido)-2-phenylethyl)boronic acid; ( -1-(3-(1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)propanamido)-2-phenylethyl)boronic acid; and ( -1-(3-(1-(2-cyano-4-methylpent-2-enoyl)piperidin-2-yl)propanamido)-2-phenylethyl)boronic acid; an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds. ( -1-(3-(( -1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methoxy)propanamido)-2-phenylethyl)boronic acid; ( -1-(3-(1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)propanamido)-2-phenylethyl)boronic acid; and ( -1-(3-(1-(2-cyano-4-methylpent-2-enoyl)piperidin-2-yl)propanamido)-2-phenylethyl)boronic acid; an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.